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The effects of valsartan on the accumulation of circulating and
renal advanced glycation end products in experimental dia-
betes.
Background. Blockade of the RAS with the ACE inhibitor
ramipril prevents the accumulation of advanced glycation end
products (AGEs) in experimental diabetes. Although AT1 re-
ceptor antagonists may inhibit AGE formation in vitro, their
effect in normotensive animals with type 1 diabetes has not
been established.
Methods. Streptozotocin-induced diabetic and control ani-
mals were randomized (N = 10/group) to receive the AT1 an-
tagonist valsartan at a dose of 30 mg/kg/day by oral gavage for
24 weeks, or no intervention. Renal and plasma AGE accumu-
lation was correlated with renal functional parameters.
Results. Valsartan reduced the albumin excretion rate con-
sistent with its renoprotective effects. Renal and skin collagen
accumulation of the non-fluorescent AGE carboxymethyllysine
(CML) were increased in animals with diabetes, but normal-
ized following treatment with valsartan. Renal fluorescence and
skin collagen pentosidine levels were also increased by diabetes.
However, valsartan only provided a modest attenuation of these
parameters. In addition, diabetes was associated with increased
plasma fluorescence, which was unaffected by AT1 antagonism.
Conclusion. Renoprotective doses of valsartan are associated
with a significant reduction in the accumulation of tissue and
plasma CML. These effects were not the same for all AGEs,
suggesting combination approaches will be required to optimize
renoprotection in diabetes.
Blockade of the renin-angiotensin system (RAS) is
one of the most important interventions in patients
with diabetic kidney disease [1]. Its benefits have been
attributed to interruption of both hemodynamic and
non-hemodynamic pathways that lead to progressive
nephropathy [2, 3]. In particular, recent studies have sug-
gested that blockade of the RAS may be able to inhibit the
formation of advanced glycation end products (AGEs).
AGEs are known to be major independent contributors
to diabetic nephropathy because blockade of their for-
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mation has proven beneficial in experimental diabetic
nephropathy in the presence of ongoing hyperglycemia
[4–6]. Both ACE inhibitors and angiotensin receptor type
1 (AT1) antagonists are able to inhibit AGE formation
in vitro in the absence of a functioning RAS. Further-
more, recent studies by our group using the ACE inhibitor
ramipril have suggested that these agents may be equally
potent in vivo [7]. This study aims to determine whether
renoprotective therapy with the AT1 receptor antagonist
valsartan has similar effects on AGE accumulation in an
experimental model of type 1 diabetes.
METHODS
Experimental rodent model
Experimental diabetes was induced in male Sprague-
Dawley rats (200-250 g) by injection of streptozotocin
(50 mg/kg) [7]. Diabetic and control animals were ran-
domized (N = 10/group) to receive no treatment (D and
C), or the AT1 antagonist valsartan (CAT1 and DAT1)
at a dose of 30 mg/kg/day by oral gavage for 24 weeks.
Two units of Ultralente insulin (Ultratard HM; Novo In-
dustries, Bagsvaerd, Denmark) were administered daily
to diabetic animals. Systolic blood pressure (SBP) was
assessed by tail cuff plethysmography, albumin excre-
tion rate (AER) by radioimmunoassay, and glycated
hemoglobin (HbA1c) were measured every eight weeks.
All animal procedures were in accordance with guidelines
set by the Austin Hospital Animal Ethics Committee.
Plasma low-molecular-weight AGE fluorescence
and renal fluorescence
LMW-AGE fluorescence (Ex 370 nm, Em 440 nm) was
assayed in deproteinated, delipidated plasma samples as
described previously [8]. Renal fluorescence was deter-
mined as above in acid hydrolyzed cortical tissue as pre-
viously described [8].
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Table 1. Renal functional and structural parameters
Control + Diabetes +
Control AT1a Diabetes AT1a
N = 10 N = 10 N = 10 N = 10
Plasma Glucose 6.9 ± 0.3 6.0 ± 0.2 27.3 ± 2.5a 26.0 ± 2.5a
mmol/L
Glycated Hb % 3.1 ± 0.1 3.0 ± 0.1 14.3 ± 0.8a 14.5 ± 0.7a
Mean SBP 127 ± 3 135 ± 11 147 ± 4a 136 ± 8b,d
mmHg
AER mg/ 3.2 ×/÷ 0.8 2.1 ×/÷ 0.4 18.7 ×/÷ 10.0a 4.4 ×/÷ 0.9c
24 hr
KW:BW 5.8 ± 0.5 5.8 ± 0.5 13.5 ± 3.8a 12.2 ± 2.0a
ratio × 10−3
Abbreviations are: SBP, systolic blood pressure; AER, 24-hour albumin
excretion rate.
aP < 0.001 vs. C.
bP < 0.05 vs. C
cP < 0.001 vs. D.
dP < 0.05 vs. D.
Isolation of skin collagen and analysis of AGEs
Rat skin collagen was prepared as described previ-
ously [5]. The AGE, Nξ(carboxymethyl)lysine (CML),
was quantified by isotope dilution, selected ion mon-
itoring gas chromatography-mass spectrometry (SIM-
GC/MS) [9], and normalized to the parent amino acid
lysine. Pentosidine was analyzed by RP-HPLC and was
also normalized to lysine content [9].
Immunohistochemistry for renal CML
Immunohistochemistry on formalin-fixed sections with
anti-CML antibody (4G9, 1:500; Alteon, Inc., Ramsay,
NJ, USA) was performed and quantified by computer-
aided densitometry with Optimas 6.2 software (Optimas
6.2–Video Pro-32; Bedford Park, SA, Australia) as de-
scribed previously [10]. Results are expressed as the per-
centage area of positive immunostaining.
RESULTS AND DISCUSSION
Diabetes was associated with a marked increase in
plasma and tissue AGEs. Renoprotective therapy with
the AT1 receptor antagonist valsartan reduced both re-
nal (Table 1) and skin levels of the non-fluorescent AGE,
CML to levels seen in control animals (Fig. 1). This is
consistent with recent studies demonstrating similar ef-
fects on CML accumulation using AT1 antagonists in a
model of type 2 diabetes [12]. The mechanism of this ef-
fect remains to be established. As this activity may be
demonstrated in vitro, it is possible that these agents in-
terfere with the formation of carbon-centered radicals
and hydroxyl radicals, possibly by metal chelation and
the scavenging of reactive oxygen species [11]. Certainly,
in vivo blockade of the RAS with ramipril reduces the for-
mation of ROS, predominantly generated by NAD(P)H
oxidase in diabetic nephropathy [8]. Indeed, oxidation
is a key component in the generation of CML, which is
considered to be a product of glycoxidation, rather than
purely as a result of glycation alone.
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Fig. 1. Skin collagen carboxymethyllysine as measured by SIM-
GC/MS. ∗P < 0.001 vs. C, †P < 0.001 vs. D.
Table 2. Tissue and plasma AGE parameters measured
Control Diabetes
Control + AT1a Diabetes + AT1a
N = 10 N = 10 N = 10 N = 10
Renal CML % 3.25 ± 0.51 2.85 ± 0.36 9.1 ± 0.39a 3.27 ± 0.4a
Renal 4.2 ± 0.1 4.5 ± 0.6 7.0 ± 0.3a 5.5 ± 0.3a,b
Fluorescence
AU/OD 280 nm
LMW-AGE 11.0 ± 0.4 11.4 ± 0.5 17.4 ± 1.0a 17.1 ± 0.8a
fluorescence
AU/OD 280 nm
Skin pentosidine 1.37 ± 0.25 1.08 ± 0.12 2.42 ± 0.23a 1.9 ± 0.52a
pmol/mg
Hydroxyproline
CML, carboxymethyllysine.
aP < 0.001 vs. C.
bP < 0.001 vs. D.
The beneficial effect of valsartan may also be partly
conferred via blood pressure reduction. For example, an-
tihypertensive treatment with either olmesartan or hy-
dralazine was able to equally reduce AGE-accumulation
in experimental type 2 diabetes [12]. However, hyperten-
sion may be a more important driving factor for renal
injury in that model. In addition, hydralazine may have
independent AGE-lowering effects, since it is chemically
related to aminoguanidine, a potent inhibitor of AGE
formation [4]. Furthermore, the synergy between blood
pressure lowering and inhibition of advanced glycation
also make this effect more difficult to interpret. Indeed,
specific AGE inhibitors may also reduce blood pressure
[8].
Although valsartan reduced CML accumulation, its
effects on the fluorescent AGEs, including pentosidine,
were more modest (Table 2). In addition, the present
study demonstrated no attenuation of AGE-fluorescence
attributed to circulating LMW-AGEs in diabetic animals
treated with valsartan (Table 2). The difference between
fluorescent and non-fluorescent AGEs (e.g., CML) in
response to valsartan treatment is consistent with this
agent not influencing all AGEs in a similar manner. This
may not be surprising given that pentosidine can be gen-
erated from nonoxidation pathways that may not be
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blocked by AT1 antagonism [13]. In addition, although
blockade of the RAS slows the progression of renal dis-
ease in diabetes, it does not completely prevent it. Ulti-
mately, the only way to prevent nephropathy in those with
diabetes will be to disrupt all of the pathways that lead
from hyperglycemia to renal injury. It therefore seems
likely that a combination of approaches will be required
to achieve persistent renoprotection [15].
The molecular identity of the AGEs that most con-
tribute to the development of diabetic complications, in-
cluding nephropathy, has not been clearly determined. In
recent studies, Miura et al found that fluorescent AGEs
better correlated with complications in patients with type
1 diabetes than levels of pentosidine or non-fluorescent
AGEs like CML [16]. However, in another study of pa-
tients with type 1 diabetes, Beisswenger et al reported that
non-fluorescent CML-AGE levels were better associated
with the presence of complications, including retinopa-
thy and nephropathy [17]. That renoprotection was still
observed in our study despite no apparent effect on fluo-
rescent AGE formation also suggests that the dominant
pathogenic AGE ligands in diabetes may be linked to the
pathways that lead to the production of CML. Ultimately,
precise chemical modification may be of less consequence
than its binding affinity and ability to activate pathogenic
pathways.
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